What do systematic reviews say?

2 questions · 4 findings · 2 reviews · asked by two or more reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 2 · 50%GRADE not reported 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 2 · 50%High 0 · 0%

Closest answers

The findings closest to your search, judged one by one by TypeSafe's Jev model.

Direct match · question page
- Metformin vs clomiphene citrate · Adverse events (gastrointestinal)
  Metformin for ovulation induction (excluding gonadotrophins) in women with polycystic ovary syndrome 2019 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found
Direct match · question page
- Metformin combined with clomiphene citrate vs clomiphene citrate alone · Adverse events (gastrointestinal) per woman
  Metformin for ovulation induction (excluding gonadotrophins) in women with polycystic ovary syndrome 2019 · Cochrane Headline outcomes only
  OR 4.26 [2.83, 6.4]
  6 studies · 852 participants
  Moderate

Metformin vs clomiphene

Gastrointestinal adverse events · women with polycystic ovary syndrome

The review found no eligible studies for this question.

2 findings from 2 reviews · compare the 2 reviews

Metformin for ovulation induction (excluding gonadotrophins) in women with polycystic ovary syndrome 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found
Insulin‐sensitising drugs (metformin, rosiglitazone, pioglitazone, D‐chiro‐inositol) for women with polycystic ovary… 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Metformin combined with clomiphene citrate vs clomiphene

Gastrointestinal adverse events · women with polycystic ovary syndrome

Metformin combined with clomiphene citrate probably leads to higher adverse events (gastrointestinal) per woman compared with clomiphene citrate alone (moderate certainty).

2 findings from 2 reviews · compare the 2 reviews

Metformin for ovulation induction (excluding gonadotrophins) in women with polycystic ovary syndrome 2019 · Cochrane Headline outcomes only
OR 4.26 [2.83, 6.4]
6 studies · 852 participants
Moderate
Insulin‐sensitising drugs (metformin, rosiglitazone, pioglitazone, D‐chiro‐inositol) for women with polycystic ovary… 2017 · Cochrane Headline outcomes only
OR 3.97 [2.59, 6.08]
3 studies · 591 participants
Moderate